The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?
- DOI
- 10.1080/14796694.2026.2725499
- Published
- 2026 Sep
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2026.2725499,
title = {The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?},
author = {Dempke WCM and Sippel C and Fenchel K and Heinemann V and van Cutsem E and Arnold D},
year = {2026},
journal = {Future oncology (London, England)},
doi = {10.1080/14796694.2026.2725499},
url = {https://doi.org/10.1080/14796694.2026.2725499}
}RIS
TY - JOUR TI - The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror? AU - Dempke WCM AU - Sippel C AU - Fenchel K AU - Heinemann V AU - van Cutsem E AU - Arnold D PY - 2026 JO - Future oncology (London, England) DO - 10.1080/14796694.2026.2725499 UR - https://doi.org/10.1080/14796694.2026.2725499 ER -
APA
WCM, D., C, S., K, F., V, H., E, V. C., & D, A. (2026). The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2725499
Source records
- pubmed · retrieved 2026-11-10T14:35:54.124Z